A Case of Hepatitis B Virus Reactivation in a HBsAg-Negative and Anti-HBs-Positive Patient with Diffuse Large B-Cell Lymphoma after Rituximab plus CHOP Chemotherapy.
- Author:
Han Min PARK
1
;
Jae Yong SEO
;
Chung Jo CHOI
;
Jin Hee KIM
;
Bum Jun KIM
;
Yong Seol JEONG
;
Choong Kee PARK
Author Information
1. Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea. ckp@hallym.or.kr
- Publication Type:Case Report
- Keywords:
Hepatitis B virus;
Lymphoma;
Rituximab
- MeSH:
B-Lymphocytes;
Doxorubicin;
Drug Therapy*;
Hepatitis B Surface Antigens;
Hepatitis B virus*;
Humans;
Lymphoma;
Lymphoma, B-Cell*;
Male;
Middle Aged;
Vincristine;
Rituximab
- From:Soonchunhyang Medical Science
2014;20(2):168-171
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The reactivation of hepatitis B virus (HBV) is well known complication among lymphoma patient related with chemotherapy. Rituximab is monoclonal antibody that targets B-lymphocytes for treatment of lymphoma and it increases reactivation of HBV. Although most of reactivation occurs in HBV carrier, it can also rarely occur when hepatitis B surface antigen (HBsAg) is negative. Furthermore it is less frequently reported in lymphoma patient when HBV serology shows HBsAg is negative and anti-HBs is positive. We report a case of HBV reactivation following 6 cycle of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for diffuse large B-cell lymphoma in HBsAg negative/anti-HBs positive 58-year-old male, with a review of the literature.
